Literature DB >> 11687030

Domiciliary oxygen for interstitial lung disease.

A J Crockett1, J M Cranston, N Antic.   

Abstract

BACKGROUND: Retrospective survival data have suggested poor effectiveness of oxygen therapy in patients with interstitial lung disease (ILD).
OBJECTIVES: To determine the effect of domiciliary oxygen therapy on survival and quality of life in patients with a diagnosis of ILD and hypoxaemia. SEARCH STRATEGY: Randomized Controlled Trials (RCTs) were identified using the Cochrane Airways Group register and the search terms: (home OR domiciliary AND oxygen AND (Interstitial lung disease OR ILD OR pulmonary fibrosis OR IPF)). SELECTION CRITERIA: Any randomized controlled trial (RCT) in adult patients with hypoxaemia and ILD that compared long term domiciliary or home oxygen therapy with a control group. DATA COLLECTION AND ANALYSIS: Only one unpublished RCT was identified. MAIN
RESULTS: Only one trial was identified. Mortality for both the oxygen treated and control groups was approximately 91% after 3 years (Peto odds ratio 0.99, 95% confidence intervals 0.16,6.26). The effect of oxygen therapy on quality of life and physiological parameters was not reported. REVIEWER'S
CONCLUSIONS: The assumption that home oxygen therapy has a beneficial survival effect in patients with ILD has not been demonstrated in the single RCT identified.

Entities:  

Mesh:

Year:  2001        PMID: 11687030     DOI: 10.1002/14651858.CD002883

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  12 in total

1.  Oxygen treatment at home.

Authors:  G J Gibson
Journal:  BMJ       Date:  2006-01-28

Review 2.  Right ventricular dysfunction in chronic lung disease.

Authors:  Todd M Kolb; Paul M Hassoun
Journal:  Cardiol Clin       Date:  2012-05       Impact factor: 2.213

Review 3.  WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.

Authors:  Cathy Payne; Philip J Wiffen; Suzanne Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-04-07

Review 4.  Eligibility for home oxygen programs and funding across Canada.

Authors:  Yves Lacasse; Sarah Bernard; François Maltais
Journal:  Can Respir J       Date:  2015-08-25       Impact factor: 2.409

5.  Pulmonary Overlap Syndromes, with a focus on COPD and ILD.

Authors:  Katherine A Dudley; Atul Malhotra; Robert L Owens
Journal:  Sleep Med Clin       Date:  2014-09

6.  Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis.

Authors:  Amanda Belkin; Kaitlin Fier; Karen Albright; Susan Baird; Brenda Crowe; Linda Eres; Marjorie Korn; Leslie Maginn; Mark McCormick; Elisabeth D Root; Thomas Vierzba; Frederick S Wamboldt; Jeffrey J Swigris
Journal:  BMC Pulm Med       Date:  2014-11-01       Impact factor: 3.317

Review 7.  Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights.

Authors:  Paola Faverio; Federica De Giacomi; Giulia Bonaiti; Anna Stainer; Luca Sardella; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Mauro Carone; Sara Annoni; Grazia Messinesi; Alberto Pesci
Journal:  Int J Med Sci       Date:  2019-06-10       Impact factor: 3.738

Review 8.  Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis.

Authors:  Maria A Trawinska; Ruwani D Rupesinghe; Simon P Hart
Journal:  Ther Clin Risk Manag       Date:  2016-04-08       Impact factor: 2.423

Review 9.  Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns.

Authors:  Yet H Khor; Elisabetta A Renzoni; Dina Visca; Christine F McDonald; Nicole S L Goh
Journal:  ERJ Open Res       Date:  2019-09-16

10.  Pragmatic randomised controlled trial of a personalised intervention for carers of people requiring home oxygen therapy.

Authors:  Peter Frith; Ruth Sladek; Richard Woodman; Tanja Effing; Sandra Bradley; Suzanne van Asten; Tina Jones; Khin Hnin; Mary Luszcz; Paul Cafarella; Simon Eckermann; Debra Rowett; Paddy A Phillips
Journal:  Chron Respir Dis       Date:  2020 Jan-Dec       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.